Two separate groups of researchers have developed a non-invasive test for Down syndrome, using only a blood sample from the pregnant woman to examine the fetus’ DNA. While the genetic tests are still in clinical trials, experts are hailing the achievement as significant because current prenatal tests like amniocentesis require inserting a needle in the uterus, and carry a risk of miscarriage.
A biotechnology company called Sequenom says it will begin selling its test next June, while researchers from Stanford, who just published their results in the Proceedings of the National Academy of Sciences, are still planning a large-scale clinical trial. Some experts say that the results are somewhat preliminary, and should be viewed cautiously: The Stanford test has been tried on only 18 blood samples. Sequenom has tried its test on only about 400 samples and has not yet published its results in peer-reviewed journals. Still, both tests have perfect records so far: no false negatives or false positives. “This is quite simply a major step forward, if it works at all like we expect it might,” [says Down Syndrome expert] Jacob A. Canick [The New York Times].
